Exocrine pancreatic carcinoma
MONDO:0005192A carcinoma that arises from epithelial cells of the exocrine pancreas
Also known as: cancer of pancreas, cancer of the pancreas, exocrine cancer, pancreas cancer, pancreatic cancer, carcinoma of exocrine pancreas, carcinoma of the pancreas, exocrine pancreas carcinoma
3838 clinical trials for this condition and its sub-types, 205 tagged with Exocrine pancreatic carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Exocrine pancreatic carcinoma
-
Pancreatic adenocarcinoma 493 trials · 926 incl. sub-types
5 sub-types
- Pancreatic ductal adenocarcinoma 552 trials Sub-types →
- Pancreatic acinar cell carcinoma 12 trials Sub-types →
- Pancreatic intraductal papillary-mucinous neoplasm with an associated invasive carcinoma 1 trial
- Mucinous pancreas adenocarcinoma 0 trials
- Pancreatic cystadenocarcinoma 0 trials Sub-types →
-
Squamous cell carcinoma of pancreas 3 trials · 13 incl. sub-types
1 sub-type
- Pancreatic adenosquamous carcinoma 13 trials
-
Familial pancreatic carcinoma 9 trials
-
Pancreatic intraductal papillary-mucinous carcinoma 0 trials · 2 incl. sub-types
-
Pancreatic mucinous cystadenoma 1 trial
Most studied deeper sub-types
-
Pancreatic cancer radiation combo trial cut short
Disease control Stopped earlyThis study looked at whether adding a precise type of radiation (stereotactic body radiation therapy) to standard chemotherapy could better control pancreatic cancer that has spread to only a few spots in the body. The trial planned to enroll patients with limited metastases, but…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo trial for tough pancreatic cancer shows early promise
Disease control Stopped earlyThis early-stage trial tested a combination of two drugs, trametinib and hydroxychloroquine, in 25 adults with advanced pancreatic cancer that could not be removed by surgery. The main goal was to find the safest dose and understand side effects. The study was stopped early, so r…
Phase 1 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Tailored cancer therapy put to the test
Disease control Stopped earlyThis study tested a precision medicine approach for people with advanced cancers like breast, ovarian, pancreatic, prostate, or sarcoma. Researchers used genetic and protein tests to track how the cancer changes and then a team of experts recommended personalized drugs. The goal …
Phase 2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Cancer combo trial ends before it begins: only one patient enrolled
Disease control Stopped earlyThis early-phase trial aimed to test the safety of combining two drugs, adagrasib and olaparib, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The study planned to include patients with certain breast, ovarian, pancreatic, and lung canc…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Engineered immune cells take on pancreatic cancer in early trial
Disease control Stopped earlyThis early-phase study tested a treatment called huCART-meso cells, which are a patient's own immune cells modified to recognize and attack pancreatic cancer cells. The trial included 54 people with advanced pancreatic cancer that could not be removed by surgery. The main goal wa…
Phase 1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental pancreatic cancer combo trial halted early
Disease control Stopped earlyThis study tested an experimental drug called APG-1387 combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in people with advanced pancreatic cancer. The goal was to find the safest dose and see if the combination could shrink tumors. However, the trial was termi…
Phase 1/2 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New cancer drug trial halted early – what we know
Disease control Stopped earlyThis early-stage trial tested an experimental drug called NUV-868, alone or with other cancer drugs, in 82 adults with advanced solid tumors (including ovarian, pancreatic, prostate, and breast cancers). The goal was to find safe doses and check for early signs of effectiveness. …
Phase 1 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Heartburn drug tested against pancreatic cancer in early trial
Knowledge-focused Stopped earlyThis early-phase study tested whether high doses of omeprazole, a common heartburn medication, could safely change certain markers in pancreatic tumors. The trial planned to enroll 25 patients with exocrine pancreatic cancer who were scheduled for surgery. Participants took omepr…
Early phase 1 • Sponsor: University of Oklahoma • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC